143 related articles for article (PubMed ID: 34405958)
21. Rapid Infliximab Infusion in Children with Inflammatory Bowel Disease: A Multicenter North American Experience.
El-Matary W; Dykes DMH; Bauman L; Elkadri A; Carroll MW; Izaguirre MR; deBruyn J; Samson CM; Crim AM; Ali S; Grossman A
Inflamm Bowel Dis; 2017 Dec; 23(12):2104-2108. PubMed ID: 29140940
[TBL] [Abstract][Full Text] [Related]
22. The safety of infliximab infusions in the community setting.
Ducharme J; Pelletier C; Zacharias R
Can J Gastroenterol; 2010 May; 24(5):307-11. PubMed ID: 20485705
[TBL] [Abstract][Full Text] [Related]
23. Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease.
Null K; Kumar V; Lissoos T; Luo M
J Med Econ; 2018 Nov; 21(11):1102-1109. PubMed ID: 30101633
[TBL] [Abstract][Full Text] [Related]
24. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F
J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330
[TBL] [Abstract][Full Text] [Related]
25. Safety of infliximab in children with IBD: the experience of an academic center in WV.
Northcutt M; Al-Subu A; Bella B; Elitsur Y
W V Med J; 2014; 110(3):26-9. PubMed ID: 24984403
[TBL] [Abstract][Full Text] [Related]
26. Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease.
Selinger CP; Lenti MV; Clark T; Rafferty H; Gracie D; Ford AC; OʼConnor A; Ahmad T; Hamlin PJ
Inflamm Bowel Dis; 2017 Dec; 23(12):2083-2088. PubMed ID: 29140939
[TBL] [Abstract][Full Text] [Related]
27. Premedication with intravenous steroids does not influence the incidence of infusion reactions following infliximab infusions in pediatric inflammatory bowel disease patients-a case-control study.
van Wassenaer EA; Meester VL; Kindermann A; Koot BGP; Benninga MA; de Meij TGJ
Eur J Clin Pharmacol; 2019 Oct; 75(10):1445-1450. PubMed ID: 31332475
[TBL] [Abstract][Full Text] [Related]
28. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
[TBL] [Abstract][Full Text] [Related]
29. Impact of rapid infliximab infusions on access at a large academic tertiary medical center.
Pusateri A; Hatcher A; Patel N; Lehman J; Hinton A; Afzali A
Am J Health Syst Pharm; 2021 Nov; 78(22):2046-2052. PubMed ID: 34050749
[TBL] [Abstract][Full Text] [Related]
30. Safety and Tolerability of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease.
Ma D; Wong W; Aviado J; Rodriguez C; Wu H
Am J Gastroenterol; 2019 Feb; 114(2):352-354. PubMed ID: 30333541
[TBL] [Abstract][Full Text] [Related]
31. Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment.
Marits P; Landucci L; Sundin U; Davidsdottir L; Nilsson J; Befrits R; Wikström AC; Eberhardson M
J Crohns Colitis; 2014 Aug; 8(8):881-9. PubMed ID: 24486178
[TBL] [Abstract][Full Text] [Related]
32. Short article: Remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease.
Kuin S; Stolte SB; van den Brink GR; Ponsioen CY; Fockens P; D'Haens GR; Löwenberg M
Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):222-5. PubMed ID: 26566062
[TBL] [Abstract][Full Text] [Related]
33. A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study.
Lee TW; Singh R; Fedorak RN
Aliment Pharmacol Ther; 2011 Jul; 34(2):181-7. PubMed ID: 21615434
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of Rapid vs Standard Infliximab Infusions in the Pediatric Population.
Rozette NA; Hellauer CM; McKee C; Vazifedan T; Gabriel CA; Dice JE; Yokois NU
Inflamm Bowel Dis; 2018 Aug; 24(9):2007-2014. PubMed ID: 29788416
[TBL] [Abstract][Full Text] [Related]
35. Can Subcutaneous Infliximab Replace Dose-Intensified Intravenous Administration in Inflammatory Bowel Disease?
Little RD; Ward MG; Sparrow MP
Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2430-2431. PubMed ID: 36155249
[No Abstract] [Full Text] [Related]
36. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
Smith PJ; Critchley L; Storey D; Gregg B; Stenson J; Kneebone A; Rimmer T; Burke S; Hussain S; Yi Teoh W; Vazeille S; Serna S; Steel A; Derbyshire E; Collins P; Dibb M; Flanagan P; Probert C; Verma AM; Subramanian S
J Crohns Colitis; 2022 Sep; 16(9):1436-1446. PubMed ID: 35390141
[TBL] [Abstract][Full Text] [Related]
37. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality.
Caspersen S; Elkjaer M; Riis L; Pedersen N; Mortensen C; Jess T; Sarto P; Hansen TS; Wewer V; Bendtsen F; Moesgaard F; Munkholm P;
Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1212-7; quiz 1176. PubMed ID: 18848503
[TBL] [Abstract][Full Text] [Related]
38. Tolerability of one hour 10 mg/kg infliximab infusions in patients with inflammatory bowel disease.
Babouri A; Buisson A; Bigard MA; Peyrin-Biroulet L
J Crohns Colitis; 2013 Mar; 7(2):129-33. PubMed ID: 22472090
[TBL] [Abstract][Full Text] [Related]
39. Dashboard-Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity.
Dubinsky MC; Mendiolaza ML; Phan BL; Moran HR; Tse SS; Mould DR
Inflamm Bowel Dis; 2022 Sep; 28(9):1375-1385. PubMed ID: 34978325
[TBL] [Abstract][Full Text] [Related]
40. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
